Dr. David Clark is a senior patent counselor at Wilson Sonsini Goodrich & Rosati. He assists with the preparation and prosecution of patent applications in the fields of chemistry, pharmaceuticals, and clean technology. David also provides support on various matters relating to intellectual property counseling, including freedom to operate and validity analysis. He has been a registered patent agent since 2006.
David's background in chemistry includes extensive research experience as a practicing medicinal chemist with Tularik Inc. and Anadys Pharmaceuticals. He has performed research in the discovery and development of agents for the treatment of cancer, HIV and HCV infection, inflammatory disease, and hypercholesterolemia. His graduate and undergraduate studies in synthetic organic chemistry dealt with the total synthesis of complex natural products and the development of synthetic methods. David is a co-author of numerous scientific articles and is a co-inventor on 14 issued U.S. patents.
Dr. David Clark is a senior patent counselor at Wilson Sonsini Goodrich & Rosati. He assists with the preparation and prosecution of patent applications in the fields of chemistry, pharmaceuticals, and clean technology. David also provides support on various matters relating to intellectual property counseling, including freedom to operate and validity analysis. He has been a registered patent agent since 2006.
David's background in chemistry includes extensive research experience as a practicing medicinal chemist with Tularik Inc. and Anadys Pharmaceuticals. He has performed research in the discovery and development of agents for the treatment of cancer, HIV and HCV infection, inflammatory disease, and hypercholesterolemia. His graduate and undergraduate studies in synthetic organic chemistry dealt with the total synthesis of complex natural products and the development of synthetic methods. David is a co-author of numerous scientific articles and is a co-inventor on 14 issued U.S. patents.
- Ph.D., Synthetic Organic Chemistry, University of California, Berkeley, 1996Recipient, American Chemical Society, Division of Organic Chemistry Graduate Fellowship
- B.S., Chemistry, University of Texas at Arlington, 1990
- U.S. Patent and Trademark Office
- Ph.D., Synthetic Organic Chemistry, University of California, Berkeley, 1996Recipient, American Chemical Society, Division of Organic Chemistry Graduate Fellowship
- B.S., Chemistry, University of Texas at Arlington, 1990
- U.S. Patent and Trademark Office
Therapeutics and Drug Discovery
- Small molecule synthesis
- Small molecules
Chemistry and Material Science
- Chemical synthesis
- Chemistry
- Organic chemistry
- Polymorph
- Process chemistry
Miscellaneous
- Ophthalmology
Therapeutics and Drug Discovery
- Small molecule synthesis
- Small molecules
Chemistry and Material Science
- Chemical synthesis
- Chemistry
- Organic chemistry
- Polymorph
- Process chemistry
Miscellaneous
- Ophthalmology
Verdiva is advancing a portfolio of next-generation oral and injectable treatments with first-in-class or best-in-class potential. The company is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Verdiva’s most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia.
- Privacy Policy
- Terms of Use
- Accessibility